Магнезиев
Основна информация
- Търговско наименование:
- Магнезиев сулфат Тони-М прах за перорален разтвор - 30g
- Активна съставка:
- Магнезиев сулфат
- Предлага се от:
- Тони-М" ООД"
- АТС код:
- A06AD4
- INN (Международно Name):
- Magnesium sulfate
- Използвай за:
- Хората
- Вид на лекарството:
- алопатични наркотици
Документи
- за медицински специалисти:
- кратка характеристика на продукта
-
- за широката общественост:
- Информационната листовка на този продукт в момента не е на разположение, можете да изпратите заявка за нашето обслужване на клиенти и ние ще Ви уведомим веднага щом ние сме в състояние да го получи.
Искане на информационната листовка за широката общественост.
Локализация
- Предлага се в:
-
България
- Език:
- български
Терапевтична информация
- Каталог на резюме:
- Magnesium sulphate Toni-M, powder for oral solution - 30g
Друга информация
Състояние
- Източник:
- Изпълнителна агенция по лекарствата - Bulgarian Drug Agency - Bulgaria
- Номер на разрешението:
- 20040114
- Дата Оторизация:
- 09-07-2012
- Последна актуализация:
- 01-06-2018
кратка характеристика на продукта
- Информационната листовка на този продукт в момента не е на разположение, можете да изпратите заявка за нашето обслужване на клиенти и ние ще Ви уведомим веднага щом ние сме в състояние да го получи.
Искане на информационната листовка за широката общественост.
Документи на други езици са налични тук
- Достъпът до този документ е достъпен само за регистрирани потребители.
Регистрирайте се сега за пълен достъп
17-9-2018
Human medicines European public assessment report (EPAR): Triumeq, abacavir sulfate / dolutegravir sodium / lamivudine, Revision: 10, Authorised
Europe - EMA - European Medicines Agency
12-9-2018
Tromboject 1% and 3% (sodium tetradecyl sulfate) with Visible Particles - Update on the Use of Medical Grade Filters
MedEffect Canada
4-9-2018
Human medicines European public assessment report (EPAR): Elmiron, pentosan polysulfate sodium, Revision: 4, Authorised
Europe - EMA - European Medicines Agency
2-7-2018
Fagron Sterile Services Issues Voluntary Nationwide Recall of Neostigmine Methylsulfate 1mg/mL, 5mg per 5mL and Neostigmine Methylsulfate 1mg/mL, 3mg per 3mL, in a 5mL syringe Due to Mislabeling
Fagron Sterile Services is voluntarily recalling two (2) lots of Neostigmine Methylsulfate 5mL syringes to the user/hospital/clinic level. The specified product lots are being recalled because of a confirmed customer complaint that some syringe units containing Neostigmine Methylsulfate 1mg/mL, 5mg per 5mL are incorrectly labelled as Neostigmine Methylsulfate 1mg/mL, 3mg per 3mL. Secondary packages are properly labelled as Neostigmine Methylsulfate 1mg/mL, 5mg per 5mL.
FDA - U.S. Food and Drug Administration
29-6-2018
Orphan designation: (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate (larotrectinib), for the: Treatment of soft tissue sarcoma
Europe - EMA - European Medicines Agency
19-6-2018
Opinion/decision on a Paediatric investigation plan (PIP): -, Plazomicin (sulfate), Therapeutic area: Infectious diseases
Europe - EFSA - European Food Safety Authority EFSA Journal
8-5-2018
Human medicines European public assessment report (EPAR): Elmiron, pentosan polysulfate sodium, Revision: 3, Authorised
Europe - EMA - European Medicines Agency
3-5-2018
Orphan designation: 6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-α-L-talofuranosyl)-paromamine sulfate, for the: Treatment of mucopolysaccharidosis type I
Europe - EMA - European Medicines Agency
8-9-2009
Decision on future reimbursement status of medicinal products in ATC group A06 (laxatives) and A02AA04 (magnesium compounds)
On 3 september 2009, the Danish Medicines Agency decided on the future reimbursement status of medicinal products in ATC group A06 (laxatives) and A02AA04 (magnesium compounds).
Danish Medicines Agency
4-5-2009
Consultation on the reimbursement status of medicinal products in ATC group A06 (laxatives) and A02AA04 (magnesium hydroxide)
At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products authorised for marketing in Denmark in ATC group A06 (laxatives) and A02AA04 (magnesium hydroxide)
Danish Medicines Agency
27-6-2018
EU/3/15/1606 (Bayer AG)
EU/3/15/1606 (Active substance: (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate) - Transfer of orphan designation - Commission Decision (2018)4094 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/184/15/T/02
Europe -DG Health and Food Safety
1-6-2018
Valproate
Valproate (Active substance: medicinal products containing substances related to valproate (sodium valproate, valproic acid, valproate semisodium, valpromide, valproate magnesium)) - Community Referrals - Art 31 - Commission Decision (2018)3623 of Fri, 01 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/A-31/1454
Europe -DG Health and Food Safety
14-5-2018
Girolan and its associated name Apralan
Girolan and its associated name Apralan (Active substance: Apramycin sulfate) - Community Referrals - Art 34 - Commission Decision (2018)2989 of Mon, 14 May 2018 European Medicines Agency (EMA) procedure number: EMEA/V/A/122
Europe -DG Health and Food Safety
21-3-2018
EU/3/16/1714 (IQVIA RDS Ireland Limited)
EU/3/16/1714 (Active substance: 6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-a-L-talofuranosyl)-paromamine sulfate) - Transfer of orphan designation - Commission Decision (2018)1823 of Wed, 21 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/119/16/T/01
Europe -DG Health and Food Safety